ESMO21: novel drug combination improves survival for prostate cancer

Recently presented at the ESMO Congress 2021 (16–21 September 2021), the PEACE-1 and STAMPEDE studies have discovered that the addition of abiraterone acetate plus prednisolone (APP) to standard therapy for hormone/castration-sensitive prostate cancer lengthened survival compared to standard therapy alone. For metastatic prostate cancer, androgen-deprivation therapy (ADT) was standard of care for decades. Since 2015, docetaxel and abiraterone have both separately shown to improve survival when added to ADT. However, until now, it was unknown whether one or both agents should be added to ADT to achieve the best outcomes. PEACE-1 is the first trial to demonstrate that using three...